Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Tuesday 26 May 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Digital

pharmaphorum podcast Episode 261 - Kris Kaneta, Norstella

Trustworthy and novel AI in clinical trial planning, with Kr...

Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials

R&D

applicants for hiring process sit against a gray painted brick wall

Changing Faces: Pharma and biotech, April 2026

April didn’t see too much activity at the big pharmas, but saw plenty of executive movement at small and midsized biotechs.

Sales & Marketing

lady looking at device, with a colourful background

Sponsored

Solution Spotlight: InConcert for pre-launch

Inizio InConcert brings together engagement data, field insight, and clinical indicators to help teams see how readiness is taking shape.

Digital

Digital health concept

The NHS 10-Year Plan will only succeed if digital health mee...

The NHS 10-Year Plan defines three core pillars that are set to revolutionise how we receive care.

R&D

Why UCB bet a billion dollars on cell therapy for epilepsy

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

R&D

Scientist in lab coat uses AI for biological research

When biology becomes a language: Biodata teaching

Dr Shai Melcer, head of bio-convergence at the Israel Innovation Authority, discusses biology as a language ahead of Biomed Israel 2026.

R&D

Microscope and test tubes

On the ICH E20 draft guideline (2025) for adaptive clinical ...

A review of the scope, key principles, methodological expectations, and regulatory implications of ICH E20.

R&D

Sandoz hq

Sandoz on the future of generics and biosimilars in Europe

At Reuters Pharma Europe, Sandoz' Claire D'Abreu-Hayling explored the promise of the so-called “golden decade” of patent expiry for generics.

Load more results

Sales & Marketing

Sales & Marketing

lady looking at device, with a colourful background

Sponsored

Solution Spotlight: InConcert for pre-launch

Inizio InConcert brings together engagement data, field insight, and clinical indicators to help teams see how readiness is taking shape.

Sales & Marketing

women in discussion

Sponsored

Company Profile: Inizio Ignite

Inizio Ignite is the global advisory partner for health and life sciences, encompassing connected expertise across its ecosystem.

Digital

Digital

pharmaphorum podcast Episode 261 - Kris Kaneta, Norstella

Trustworthy and novel AI in clinical trial planning, with Kr...

Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials

Digital

Digital health concept

The NHS 10-Year Plan will only succeed if digital health mee...

The NHS 10-Year Plan defines three core pillars that are set to revolutionise how we receive care.

Market Access

Market Access

The borders of Europe at night

Innovation beyond invention will bring novel medicines to Eu...

Unlocking the potential of novel medicines for Europe’s patients demands innovation beyond invention.

Market Access

pharma commercialisation concept - hcp and laptop and metrics

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.

Editor's Picks

GBL joins CVC in €10.7bn takeover bid for Recordati

After refusing to resign, CDER head Høeg is fired

As Ebola deaths climb, search begins for vaccine

NICE changes stance on Genmab's cervical cancer drug

Remepy's hybrid Parkinson's therapy poised for phase 3

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Cancer cell and T-cell

CAR-NK cell therapies for solid tumours: Closing the gap bet...

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

Oncology

hcp and patients and dose optimisation in clinic with nurses

Dose optimisation in oncology: Insights from AACR 2026 and i...

Five years after its launch, the FDA’s Project Optimus remained a key theme in discussions at AACR 2026.

Oncology

Precision medicine, DNA on target

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Patients

Patients

pharmaphorum podcast Episode, 260 - Ramy Younes, Boehringer Ingelheim

The cardio-renal-metabolic space and obesity as a chronic di...

The podcast welcomes Dr Ramy Younes, corporate VP, global head of clinical development, cardiorenalmetabolism, at Boehringer Ingelheim.

Patients

A hand grabs and breaks a DNA chain to represent biohacking

Why biohackers are ditching vague health metrics

Precision diagnostics enable targeted therapeutics.

Patients

Hands in a circle point to the middle where EU stars are, blue background

Stronger together: The future of psychiatry in a changing Eu...

Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.

R&D

R&D

applicants for hiring process sit against a gray painted brick wall

Changing Faces: Pharma and biotech, April 2026

April didn’t see too much activity at the big pharmas, but saw plenty of executive movement at small and midsized biotechs.

R&D

Why UCB bet a billion dollars on cell therapy for epilepsy

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

R&D

Pipette and test tubes

Bridging ethics and efficacy in IRB review of vaccine trials

Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.

Editor's Picks

GBL joins CVC in €10.7bn takeover bid for Recordati

After refusing to resign, CDER head Høeg is fired

As Ebola deaths climb, search begins for vaccine

NICE changes stance on Genmab's cervical cancer drug

Remepy's hybrid Parkinson's therapy poised for phase 3

Digital

pharmaphorum podcast Episode 261 - Kris Kaneta, Norstella

Trustworthy and novel AI in clinical trial planning, with Kr...

Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company